European Journal of Cancer

Volume 27, 1991

List of Contents and Author Index

Published by
PERGAMON PRESS Oxford · New York · Seoul · Tokyo

European Journal of Cancer

Editor in Chief:

MICHAEL PECKHAM
Director of Research and Development Department of Health

Editorial Office:

European Journal of Cancer, British Postgraduate Medical Federation, 33 Millman Street, London, WC1N 3EJ, UK
Telephone 44-71-430-0100
Fax 44-71-430-0072

Editors:

MATTI AAPRO
Centre Anticancéreux, Clinique de Genolier, 1261 Genolier, Switzerland

PETER BOYLE
Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia, Milan, Italy

WERNER FRANKE
Institute of Cell and Tumor Biology German Cancer Research Center, Heidelberg, Germany

EMMANUEL VAN DER SCHUEREN
Universitair Ziekenhuis St Rafaël, Leuven, Belgium

UMBERTO VERONESI
Istituto Nazionale Tumori, Milan, Italy

European Journal of Cancer Part B: Oral Oncology

CRISPIAN SCULLY
Centre for the Study of Oral Disease, Bristol Dental Hospital, Lower Maudlin Street, Bristol BS1 2LY, UK

Senior Advisors

Kari Alitalo, Harry Bartelink, Henri Bismuth, Walter Bodmer, Gianni Bonadonna, Piet Borst, Frans Cleton, Derek Crowther, Louis Denis, Jean-Pierre Gerard, Jack Hardcastle, Jean-Claude Horiot, Gordon McVie, Jacques Ninane, Jens Overgaard, Thierry Philip, Herbert Pinedo, Manfred Rajewsky, Bruno Salvadori, Harald Stein

Consulting Editors

Molecular Biology
A Balmain
M Beato
T Boon
C-H Heldin
M Yaniv

Cell Biology
G Gabbiani
B Geiger
D Louvard
E Rozengurt
J M Vasiliev

Genetics
F Cuzin
G P Georgiev
A Hagemeijer
G Klein
H Lehrach

Biochemistry
M M Burger
P A Cerutti
C G Gahmberg
F Oesch

Molecular Diagnostics
B Groner
J P Mach
C Marshall
G Riethmuller

Molecular Therapeutics
T Hercend
C Huber
S Meuer

Radiotherapy
D Ash
F Eschwege
R Greiner
A Horwich
D Kogelnik
P Scalliet
I Turesson
A Vritsios
O Dahl

Tumour Virology
L Crawford
H Diggelman
H zur Hausen
P Tiollais

Radiobiology
G Adams
A van der Kogel
G Steel

Pathology
P Bannasch
J Costa
B Gusterson
F Rilke

Imaging, Interventional Radiology, Medical Physics
A Breit
R S Dondelinger
D Gadian
J-H Svensson

Biotechnology and Industry
S Foden

Medical Oncology
F Cavalli
M Clavel
H H Hansen
A Harris
R Mertelsmann
S Monfardini
A van Oosterom
J F Smyth

Pharmacology and New Drug Development
J P Armand
M D'Incalci
S B Kaye
P Workman
G Schwartsmann

Paediatric Oncology
H Jurgens
J Pritchard
D Sommelet-Olive
P A Voûte

Endocrinology
K Griffiths
S Lamberts
C Mahler

Haematology
M Boiron
M H Bronchud
T M Dexter
G Gahrton

Psychosocial Issues
A Cull
P Maguire
R Zittoun

Surgery
G Chisholm
F Demard
J van Dongen
I S Fentiman
U Metzger
A Peracchia
P Schlag

Epidemiology and Cancer Prevention
J Cuzick
N E Day
R Saracci
C La Vecchia
D Zaridze
W Zatonski

Clinical Trial Methodology, Biostatistics
M Buyse
R Flamant
E Marubini

Palliative Oncology
J Maher
H J Senn
M Slevin
V Ventafridda

Ethics
M Baum

Education
A Costa

Corresponding Editors

North America
C Balch, Z Fuks, C Henderson, V C Jordan, A Knudson, H Koprowski, J Minna, L Peters, D Raghavan, E J Stanbridge

Japan
Y Nishizuka

India
I Mittra

Australia
A Langlands, V Marshall, D Metcalf, R Stuart-Harris, R Sutherland, M Tattersall, H R Withers

Society and News Correspondents

EORTC	F Meunier	FECS	P Pritchard
ESO	V Majstorovic	ESTRO	J W H Leer
ESMO	H Cortes-Funes	EACR	M R Price
EC	A Vanvossel	EACL	O Bang
ESSO	W Mattheiem	SIOP (European Branch)	J Plaschkes

Editor in Chief's Office
Scientific Editor David McNamee
Editorial Assistant Sarah Hole

Production Editor (Pergamon) H M Vella

LIST OF CONTENTS

NUMBER 1

Comments and Critique

S. F. Lowry — 1 — Cancer cachexia revisited: old problems and new perspectives

P. Scalliet — 3 — Radiotherapy in the elderly

— 5 — Classified section

Fax Communication

P. R. Twentyman and K. A. Wright — 6 — Failure of GM-CSF to influence the growth of small cell and non-small cell lung cancer cell lines *in vitro*

Papers

A. Hyltander, C. Drott, U. Körner, R. Sandström and K. Lundholm — 9 — Elevated energy expenditure in cancer patients with solid tumours

A. Hyltander, I. Warnold, E. Edén and K. Lundholm — 16 — Effect on whole-body protein synthesis after institution of intravenous nutrition in cancer and non-cancer patients who lose weight

C. Tarella, D. Ferrero, M. Bregni, S. Siena, E. Gallo, A. Pileri and A. M. Gianni — 22 — Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF

Specialist Interest Articles

R. P. Abratt, P. A. Willcox, M. de Groot, H. T. Goodman, E. R. Jansen and D. G. M. Salton — 28 — Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma

S. Merry, T. G. Hamilton, P. Flanigan, R. I. Freshney and S. B. Kaye — 31 — Circumvention of pleiotropic drug resistance in subcutaneous tumours *in vivo* with verapamil and clomipramine

B. Salvadori, C. Bartoli, S. Zurrida, V. Delledonne, P. Squicciarini, D. Rovini and L. Barletta — 35 — Risk of invasive cancer in women with lobular carcinoma *in situ* of the breast

D. Thiébaud, S. Leyvraz, V. von Fliedner, L. Perey, P. Cornu, S. Thiébaud and P. Burckhardt — 37 — Treatment of bone metastases from breast cancer and myeloma with pamidronate

H. Hamed, M. Caleffi, I. S. Fentiman, B. Thomas and R. D.Bulbrook — 42 — Steroid hormones in lymph and blood from women with early breast cancer

G. Secreto, C. Recchione, P. Ballerini, L. Callegari, A. Cavalleri, A. Attili, G. Fariselli, D. Moglia and I. Del Prato — 44 — Accumulation of active androgens in breast cyst fluids

Y. Chin, L. Plessers, J. Vandepitte and J. Raus — 48 — A murine monoclonal antibody to human breast cancer cells associated with DNA ploidy status

G. Scambia, P. B. Panici, F. Battaglia, G. Ferrandina, G. Baiocchi, A. Gallo, G. Sica and S. Mancuso — 51 — Effect of recombinant human interferon-alpha$_{2b}$ on receptors for steroid hormones and epidermal growth factor in patients with endometrial cancer

R. Peck and W. Bollag — 53 — Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines

M. P. Colombo, G. Ferrari, G. Biondi, D. Galasso, C. C. Howe and G. Parmiani — 58 — Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts

W. J. Zeller, S. Frühauf, G. Chen, B. K. Keppler, E. Frei and M. Kaufmann — 62 — Chemoresistance in rat ovarian tumours

L. M. Mir, S. Orlowski, J. Belehradek Jr and C. Paoletti — 68 — Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses

J. Belehradek Jr, S. Orlowski, B. Poddevin, C. Paoletti and L. M. Mir — 73 — Electrochemotherapy of spontaneous mammary tumours in mice

J. Hurtado, P. Esbrit and A. Rapado — 76 — Relative role of bone and kidney in the hypercalcaemia associated with the rat Walker carcinosarcoma 256

L.-M. Ching, W. R. Joseph, L. Zhuang, G. J. Atwell, G. W. Rewcastle, W. A. Denny and B. C. Baguley — 79 — Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity

H. Swoboda and H.-P. Friedl — 83 — Incidence of cancer of the respiratory and upper digestive tract in urban and rural eastern Austria

F. Levi, S. Franceschi, C. La Vecchia, E. Negri, C. Gulie, G. Duruz and B. Scazziga — 85 — Previous thyroid disease and risk of thyroid cancer in Switzerland

Feature Articles

M. F. Fey, A. E. Kulozik, T. E. Hansen-Hagge and A. Tobler — 89 — The polymerase chain reaction: a new tool for the detection of minimal residual disease in haematological malignancies

C. La Vecchia, P. Boyle, S. Franceschi, F. Levi, P. Maisonneuve, E. Negri, F. Lucchini and M. Smans — 94 — Smoking and cancer with emphasis on Europe

Book Review

J. Serpell — 105 — *Detection and Treatment of Early Breast Cancer* by I. S. Fentiman

News — 105

Letters

J. T. Leith and S. Michelson — 108 — Suramin and tumour cell radiosensitivity

M. Jirsa Jr, P. Poučková, J. Doležal, J. Pospíšil and M. Jirsa — 109 — Hyperbaric oxygen and photodynamic therapy in tumour-bearing nude mice

W. Hoeltl, Ch. Gabriel and M. Marberger — 110 — Asynchronous bilateral testicular tumour without previous carcinoma *in situ*

Correction — 110

NUMBER 2

Comments and Critique

J. Meharchand and I. Tannock — 111 — Quality control in chemotherapy

P. Boyle — 112 — Cancer incidence registration

S. Greggi, B. A. J. Ponder and S. Mancuso — 113 — Establishment of a European registry for familial ovarian cancer

Papers

M. Frenay, G. Milano, J. L. Formento, M. Francoual, J. L. Moll and M. Namer — 115 — Oestrogen and progesterone receptor status in bone biopsy specimens from patients with breast cancer

F. Roila, C. Basurto, S. Bracarda, M. Sassi, M. Lupattelli, M. Picciafuoco, E. Boschetti, M. Tonato and A. Del Favero — 119 — Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis

U. Räth, M. Kaufmann, H. Schmid, J. Hofmann, B. Wiedenmann, A. Kist, J. Kempeni, E. Schlick, G. Bastert, B. Kommerell and D. Männel — 121 — Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites

Specialist Interest Articles

A. R. Miserez, I. Günes, J. Müller-Brand, E. Walther, R. Fridrich and H. Mäcke — 126 — Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3

C.-c. Hsieh and D. Trichopoulos — 131 — Breast size, handedness and breast cancer risk

G. Weiss, S. Green, D. S. Alberts, J. T. Thigpen, H. E. Hines, K. Hanson, H. I. Pierce, L. H. Baker and J. W. Goodwin — 135 — Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study

R. G. Mehta, R. C. Moon, M. Hawthorne, F. Formelli and A. Costa — 138 — Distribution of fenretinide in the mammary gland of breast cancer patients

G. Giaccone, G. Schmidt and A. Calciati — 141 — Pilot study of teniposide in combination chemotherapy for small cell lung cancer

J. H. J. Martin, B. M. McKibben, M. Lynch and H. W. van den Berg — 143 — Modulation by oestrogen and progestins/antiprogestins of alpha interferon receptor expression in human breast cancer cells

A. G. Nanninga, E. G. E. de Vries, P. H. B. Willemse, B. E. Oosterhuis, D. Th. Sleijfer, H. J. Hoekstra and N. H. Mulder — 147 — Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port

K. E. Crannage, K. Rogers, G. Jacob, C. J. Stoddard, W. E. G. Thomas, C. W. Potter and R. C. Rees — 149 — Factors influencing the establishment of tumour-infiltrating lymphocyte cultures from human breast carcinoma and colon carcinoma tissue

O. Sanfilippo, E. Ronchi, C. De Marco, G. Di Fronzo and R. Silvestrini — 155 — Expression of P-glycoprotein in breast cancer tissue and *in vitro* resistance to doxorubicin and vincristine

J. Benítez, J. M. Ladero, C. Jara, J. A. Carrillo, J. Cobaleda, A. Llerena, E. Vargas and J. J. Muñoz — 158 — Polymorphic oxidation of debrisoquine in lung cancer patients

A. C. M. Martens, C. J. de Groot and A. Hagenbeek	161	Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia
A. Eardley, A. Cribb and L. Pendleton	166	Ethical issues in psychosocial research among patients with cancer
S. Bindemann, M. Soukop and S. B. Kaye	170	Randomised controlled study of relaxation training
E. Archimbaud, D. Guyotat, J. Maupas, C. Ploton, A. Nageotte, Y. Devaux, X. Thomas, J. Fleurette and D. Fiere	174	Pefloxacin and vancomycin vs. gentamicin, colistin sulphate and vancomycin for prevention of infections in granulocytopenic patients: a randomised double-blind study
J. G. W. Greaves-Otte, J. Greaves, P. M. Kruyt, O. van Leeuwen, J. C. van der Wouden and E. van der Does	178	Problems at social re-integration of long-term cancer survivors
P. Matthys, H. Heremans, G. Opdenakker and A. Billiau	182	Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia
M. L. Marcante and A. Venuti	187	Human papillomavirus DNA as a possible index of invasiveness in female genital tract carcinomas
N. Shimizu, H. Yamashiro, A. Murakami, R. Hamazoe and M. Maeta	190	Diagnostic accuracy of combination of assays for immunosuppressive acidic protein and carcinoembryonic antigen in detection of recurrence of gastric cancer
M. R. Cardillo, R. Marino and V. Pozzi	193	Human papillomavirus DNA in cervical intraepithelial neoplasia detected by *in situ* hybridisation
S. Pyrhönen, A. Laasonen, L. Tammilehto, J. Rautonen, S. Anttila, K. Mattson and L. R. Holsti	197	Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma

Feature Articles

K. Vantongelen, W. Steward, G. Blackledge, J. Verweij and A. Van Oosterom	201	EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials
F. Levi, V.-C. Te, L. Randimbison and C. La Vecchia	207	Cancer incidence registration and trends in the Canton of Vaud, Switzerland
J.-Cl. Chevrolet and Ph. Jolliet	210	An ethical look at intensive care for patients with malignancies
News	213	

Letters

J. M. Buesa, R. Fernández, F. J. Barón, I. Palacio, J. Cueva, E. Esteban and J. M. Gracia	215	Dacarbazine in advanced squamous cell carcinoma of the head and neck
J. B. Vermorken, S. Tumolo, K. J. Roozendaal, J.-P. Guastalla, T. A. W. Splinter and J. Renard	216	5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix
E. E. Vokes, M. J. Ratain, L. Janisch, P. C. Hoffman, H. M. Golomb and R. L. Schilsky	217	A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients
N. L. T. Carlsen	219	Maturation of neuroblastomas
D. H. Schweitzer, P. M. Edelbroek, F. A. de Wolff and H. J. Keizer	219	Acute reversible neurotoxicity after intrathecal low-dose methotrexate
S. Gundersen and A. Flokkmann	220	Interferon plus dacarbazine in advanced malignant melanoma: a phase I–II study
P. Sowbhagya, V. R. Sastry Kolluri, D. K. Subba Krishna, S. Das, B. S. Das and G. N. Narayana Reddy	221	Intracranial tumours and blood groups
V. N. Bhattathiri, L. Sudha, B. Rajasekharan Pillai, A. Sudhakaran, K. Sasidharan and M. K. Nair	222	Periodontal space: major route to bone in oral cancer

NUMBER 3

Comments and Critique

M. A. H. Russell and M. J. Jarvis	223	Skin patches to prevent lung cancer
P. Scalliet	225	The trouble with neutrons
M. Aapro	230	European Winter Oncology Conference (EWOC)

Papers

Members of the EORTC Clonogenic Assay Screening Study Group — 231 — Human granulocyte–macrophage colony-stimulating factor modulates *in vitro* growth in only a minority of continuous human tumour cell lines

D. P. Dearnaley, M. G. Ormerod and J. P. Sloane — 236 — Micrometastases in breast cancer: long-term follow-up of the first patient cohort

Specialist Interest Articles

J. M. Kurtz, J. Jacquemier, R. Amalric, H. Brandone, Y. Ayme, D. Hans, C. Bressac and J.-M. Spitalier — 240 — Is breast conservation after local recurrence feasible?

N. Andrieu, F. Clavel, A. Auquier, B. Gairard, A. Brémond, J. Lansac, L. Piana, R. Flamant and R. Renaud — 244 — Association between breast cancer and family malignancies

M. E. L. van der Burg, A. M. Hoff, M. van Lent, C. J. Rodenburg, W. L. J. van Putten and G. Stoter — 248 — Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy

B. J. M. Braakhuis, G. W. M. Visser, I. Stringer and G. J. Peters — 250 — *In vitro* antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides

G. G. Steger, F. Wrba, R. Mader, O. Schlappack, C. Dittrich and H. Rainer — 254 — Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses

V. Troger, E. Francois, M. Frenay, M. Namer and G. Milano — 256 — Analysis of tissue platinum distribution in patients with cancer of the oesophagus

S. Pearce, M. Dowsett and J. A. McKinna — 259 — Albumin-bound and non-protein-bound oestradiol and testosterone in postmenopausal breast disease

G. J. Peters, C. J. van Groeningen, E. J. Laurensse and H. M. Pinedo — 263 — Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate

B. C. Tanis, J. B. Vermorken, W. W. Ten Bokkel Huinink, I. Klein, H. Gall, A. T. Van Oosterom, G. Simonetti, J. G. McVie, W. J. F. Van Der Vijgh and H. M. Pinedo — 268 — Phase I study of spiroplatin

G. Giaccone — 273 — Multimodality treatment of malignant germ cell tumours of the mediastinum

T. Endo, R. Nishimura, S.-I. Teshima, H. Ohkura, S. Baba and A. Kobata — 277 — Structures of the asparagine-linked sugar chains of human chorionic gonadotropin from a patient with extragonadal germ cell tumour

Feature Articles

H. H. Grunicke — 281 — The cell membrane as a target for cancer chemotherapy

H. Vainio, E. Heseltine, L. Shuker, D. McGregor and C. Partensky — 284 — Meeting report: occupational exposures in insecticide application and some pesticides

K. Hemminki, A. Reunanen and H. Kahn — 289 — Use of DNA adducts in the assessment of occupational and environmental exposure to carcinogens

News — 292

Letters

H. Herweijer, K. Nooter, A. Beishuizen *et al.* — 297 — Expression of *mdr*1 and *mdr*3 multidrug-resistance genes in hairy cell leukaemia

R. Arriagada and L.-E. Rutqvist — 298 — Lymph-node irradiation in operable breast cancer and statistical power

298 — Reply by U. Veronesi *et al.*

M. A. Satta, L. Troncone, G. De Rosa, A. Testa, C. Rabitti and F. Monaco — 299 — Primary papillary carcinoma arising from median ectopic thyroid in multinodular goitre

S. A. Costello and R. Rampling — 299 — Meningiomas and sex hormones

M. D. Mason, M. F. Pera and S.Cooper — 300 — Possible presence of an embryonal carcinoma-associated proteoglycan in the serum of patients with testicular germ cell tumours

A. L. Jones, M. J. Dowsett, T. J. Powles, C. J. Gallagher and R. C. Coombes — 301 — Treatment of advanced breast cancer with miconazole: a potential inhibitor of peripheral oestrogen synthesis

M. B. Sert, J. Kaern and C. Trope — 302 — The close follow-up of immunosuppressed renal recipient women through colposcopy, cervical biopsy and FCM DNA content analysis

C. Evans, R. C. Stein, J. Davenport, L. Dougherty, L. Carruthers and R. C. Coombes	302	Comparison of ondansetron with dexamethasone and domperidone in the prophylaxis of non-cisplatin chemotherapy induced emesis refractory to dexamethasone
L. Gaffuri, L. Repetto, E. Rossi, C. Oliva, R. Rosso and F. Rizzo	304	Haemolitic anaemia with positive cryoglobulin test in a HIV positive man

Conference Papers

S. B. Kaye	305	Introduction to Second European Winter Oncology Conference (EWOC-2)
N. I. Nissen and D. Hovgaard	306	Controversies in the management of Hodgkin's disease
A. Engert and V. Diehl	309	Controversies in the management of non-Hodgkin lymphoma
M. Brada	315	Impact of molecular biology on our understanding of non-Hodgkin lymphoma
T. Philip and P. Biron	320	Role of high-dose chemotherapy and autologous bone marrow transplantation in the treatment of lymphoma
A. Horwich	322	Current controversies in the management of testicular cancer
L. Y. Dirix and A. T. Van Oosterom	326	Neoadjuvant and adjuvant therapy for invasive bladder tumours
J. A. Witjes and F. M. J. Debruyne	330	Optimal management of superficial bladder cancer
L. J. Denis	333	Controversies in the management of localised and metastatic prostatic cancer
H. H. Hansen and P. E. G. Kristjansen	342	Chemotherapy of small cell lung cancer
M. Clavel and A. R. Maged Mansour	349	Head and neck cancer: prognostic factors for response to chemotherapy
M. S. Aapro	356	Controlling emesis related to cancer therapy
A. Gregor	362	Controversies in the treatment of non-small cell lung cancer
D. N. Carney	366	Lung cancer biology
M. H. Bronchud	369	Haemopoietic growth factors: unravelling the secrets of blood formation
F. P. T. Hamers, W. H. Gispen and J. P. Neijt	372	Neurotoxic side-effects of cisplatin
S. B. Kaye	377	New drug development
D. Errante, E. Vaccher, U. Tirelli, S. Tumolo and S. Monfardini	380	Management of AIDS and its neoplastic complications
A. Goldhirsch, R. D. Gelber and M. Castiglione for the International Breast Cancer Study Group	389	Adjuvant therapy of breast cancer
J. C. Horiot	399	What has radiation biology contributed to the evolution of radiotherapy?

NUMBER 4

Comments and Critique

E. Gherardi	403	Growth factors and cell movement
R. R. Weichselbaum	405	Possible applications of biotechnology to radiotherapy
S. C. Schimpff	407	Infections in cancer patients: differences between developed and less developed countries?

Papers

A.D. Burden, B. A. Oppenheim, D. Crowther, A. Howell, G. R. Morgenstern, J. H. Scarffe and N. Thatcher	409	Viridans streptococcal bacteraemia in patients with haematological and solid malignancies
C. A. Brunner, J. M. Gokel, G. Riethmüller and J. P. Johnson	411	Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognosis
J. W. Koper, E. C. Zwarthoff, A. Hagemeijer, R. Braakman, C. J. J. Avezaat, M. Bergström and S. W. J. Lamberts	416	Inhibition of the growth of cultured human meningioma cells by recombinant interferon-α
B. D'Avanzo, E. Negri, A. Gramenzi, S. Franceschi, F. Parazzini, P. Boyle and C. La Vecchia	420	Fats in seasoning and breast cancer risk: an Italian case-control study
A. S. Awidi	423	Infections in adults with cancer in a developing country: a three year prospective study

Specialist Interest Articles

F. Oshita, T. Tamura, A. Kojima, K. Yamada, M. Fukuda, K. Nakagawa, Y. Ohe, Y. Sasaki, K. Eguchi, T. Shinkai, R. Ono, K. Hara and N. Saijo	427	Late toxicities and complications in three-year survivors of small cell lung cancer
R. E. Kibbelaar, K. E. C. Moolenaar, R. J. A. M. Michalides, P. C. Van Bodegom, R. G. J. R. A. Vanderschueren, S. S. Wagenaar, K. P. Dingemans, D. Bitter-Suermann, O. Dalesio, N. Van Zandwijk and W. J. Mooi	431	Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma
C. Viscoli, A. Garaventa, G. Ferrea, G. Manno, A. Taccone and A. Terragna	435	*Listeria monocytogenes* brain abscesses in a girl with acute lymphoblastic leukaemia after late central nervous system relapse
M. Giordano, A. Riccardi, M. Girino, S. Brugnatelli, P. Scivetti, R. Luoni, R. Invernizzi and E. Ascari	437	Postremission chemotherapy in adult acute non-lymphoblastic leukaemia including intensive or non-intensive consolidation therapy
R. Bassan, R. Battista, A. D'Emilio, P. Viero, P. Dragone, E. Dini and T. Barbui	441	Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia
I. S. Fentiman, C. Poole, D. Tong, P. J. Winter, H. M. O. Mayles, P. Turner, M. A. Chaudary and R. D. Rubens	447	Iridium implant treatment without external radiotherapy for operable breast cancer: a pilot study
I. S. Fentiman, J.-P. Julien, J. A. van Dongen, B. van Geel, U. Chetty and M. Coibion	450	Reasons for non-entry of patients with DCIS of the breast into a randomised trial (EORTC 10853)
G. Leo, G. Cappiello, P. Poltronieri, C. Giardina, C. Manca, C. Storelli and S. Marsigliante	452	Tamoxifen binding sites heterogeneity in breast cancer: a comparative study with steroid hormone receptors
T. M. Knight, S. Leach, D. Forman, C. Vindigni, P. Packer, S. Venitt, C. Minacci, L. Lorenzini, P. Tosi, G. Frosini, M. Marini and N. Carnicelli	456	*N*-nitrosoproline excretion in the presence and absence of gastric disease
W. E. Aulitzky, H. Tilg, G. Gastl, R. Mull, R. Flener, W. Vogel, M. Herold, M. Berger, G. Judmaier and C. Huber	462	Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial
N. Yamamoto, S. Homma, T. W. Sery, L. A. Donoso and J. K. Hoober	467	Photodynamic immunopotentiation: *in vitro* activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light
G. Los, P. Sminia, J. Wondergem, P. H. A. Mutsaers, J. Havemen, D. ten Bokkel Huinink, O. Smals, D. Gonzalez-Gonzalez and J. G. McVie	472	Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats
S. Osanto, M.T. van den Barselaar and J. T. van Dissel	478	Increased intracellular killing of bacteria *in vitro* by monocytes of patients with metastatic melanoma before and during treatment with interferon-γ and interferon-α
B. C. Baguley, K. M. Holdaway, L. L. Thomsen, L. Zhuang and L. J. Zwi	482	Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism
C. La Vecchia, F. Parazzini, E. Negri, M. Fasoli, A. Gentile and S. Franceschi	487	Anthropometric indicators of endometrial cancer risk
S. Gamulin and R. Romić-Stojković	491	Oestrogen and progesterone receptors in primary breast cancer: a population study
F. A. Soares, G. A. Magnani Landell and J. A. Mello de Oliveira	495	Pulmonary tumour embolism from squamous cell carcinoma of the oesophagus
C. A. González, M. Errezola, I. Izarzugaza, G. López-Abente, A. Escolar, M. Nebot and E. Riboli	498	Urinary infection, renal lithiasis and bladder cancer in Spain
E. Blasco, A. Gutierrez-Hoyos, M. Lojendio, A. Cosme and J. I. Arenas	501	Expression of type 1 blood group precursor in human gastric carcinoma

Feature Articles

E. Bouffet, D. Frappaz, R. Pinkerton, M. Favrot and T. Philip	504	Burkitt's lymphoma: a model for clinical oncology
D. J. Inwards and J. O. Armitage	510	Modern chemotherapeutic regimens in the management of aggressive non-Hodgkin lymphoma: can they be improved?
News	514	

Book Review

S. Powell 516 *Introduction to Radiobiology* by M. Tubiana, J. Dutreix, A. Wambersie and D. K. Bewley

Letters

A. Boscaino, L. M. Terracciano, P. Sapere and G. De Rosa 516 Yolk sac tumour of the vagina with hepatoid differentiation

D. Howel and M. Jones 518 Study design in evaluation of combined modality treatment

A. L. Jones, J. R. Hardy, D. R. Newell and I. E. Smith 519 Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer

P. S. G. J. Hupperets, M. M. F. Fickers, L. J. Schouten and G. H. Blijham 520 A phase II study with mitomycin and vindesine in metastatic pretreated breast cancer

F. Lauria, P. L. Zinzani, D. Rondelli, D. Raspadori, D. Benfenati and S. Tura 521 Continuous infusion of interleukin-2 in two relapsed high grade non-Hodgkin lymphoma patients: effectiveness and tolerability

Correction 522

NUMBER 5

Comments and Critique

P. Skrabanek 523 Who needs consensus?

C. Williams 525 The value of consensus

D. G. Gadian 526 Magnetic resonance spectroscopy as a probe of tumour metabolism

F. Rilke 528 The autopsy: its role in oncology

G. Bonadonna 530 Salvage treatments in Hodgkin's disease

J. Cummings, L. Anderson, N. Willmott and J. F. Smyth 532 The molecular pharmacology of doxorubicin *in vivo*

M. Peckham 536 The new President of the EORTC

Papers

A. C.Begg, I. Hofland and J. Kummermehr 537 Tumour cell repopulation during fractionated radiotherapy: correlation between flow cytometric and radiobiological data in three murine tumours

A. T. M. van Holten-Verzantvoort, A. H. Zwinderman, N. K. Aaronson, *et al.* 544 The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

N. J. Bundred, W. N. Scott, S. J. Davies, W. R. Miller and R. E. Mansel 549 Zinc alpha-2 glycoprotein levels in serum and breast fluids: a potential marker of apocrine activity

Specialist Interest Articles

S. Daenen, F. A. J. Muskiet, J. Marrink and M. R. Halie 552 Aggressive chemotherapy for acute leukaemia frequently causes intestinal protein leakage

B. Bono, P. Cazzaniga, V. Pini, *et al.* 556 Palliative surgery of metastatic bone disease: a review of 83 cases

L. Di Furia, A. Piga, S. Marmili, *et al.* 559 The value of necropsy in oncology

M. Bregni, S. Siena, M. Di Nicola, G. Bonadonna and A. M. Gianni 561 Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy

H. Gurney, E. S. de Campos, D. Dodwell, A. Kamthan and N. Thatcher 565 Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

EORTC Brain Tumor Group 568 Cisplatin does not enhance the effect of radiation therapy in malignant gliomas

T. Shinkai, K. Eguchi, Y. Sasaki, T. Tamura, Y. Ohe, A. Kojima, F. Oshita and N. Saijo 571 A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer

S. Kaasa, E. Thorud, J. Tausjø, E. Wist, J. F. Evensen, S. Gundersen and H. Høst 576 Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma

M. McCarthy and J. Bore 579 Treatment of breast cancer in two teaching hospitals: a comparison with consensus guidelines

C. La Vecchia, B. D'Avanzo, E. Negri and S. Franceschi	582	History of selected diseases and the risk of colorectal cancer
S. P. Toikkanen, H. P. Kujari and H. Joensuu	586	Factors predicting late mortality from breast cancer
B. Petrini, G. Wolk, J. Wasserman, I. Vedin, Ö. Strannegård, H. Blomgren and P.-L. Esposti	591	Indomethacin modulation of monocyte cytokine release following pelvic irradiation for cancer
F. Parazzini, C. La Vecchia, E. Negri, L. Bocciolone, L. Fedele and S. Franceschi	594	Oral contraceptive use and the risk of ovarian cancer: an Italian case-control study
S. Baghdiguian, B. Verrier, M. Roccabianca, G. Pommier, J. Marvaldi and J. Fantini	599	Vectorial release of carcinoembryonic antigen induced by IFN-γ in human colon cancer cells cultured in serum-free medium
S. Franceschi, E. Bidoli, R. Talamini, S. Barra and C. La Vecchia	604	Colorectal cancer in northeast Italy: reproductive, menstrual and female hormone-related factors
A. M. E. Nouri, A. Bergbaum, E. Lederer, D. Crosby, A. Shamsa and R. T. D. Oliver	608	Paired tumour infiltrating lymphocyte (TIL) and tumour cell line from bladder cancer: a new approach to study tumour immunology *in vitro*
J. de Kraker, C. A. Hoefnagel and P. A. Voûte	613	^{131}I-rose bengal therapy in hepatoblastoma patients
C. Schaake-Koning, A. Kirkpatrick, R. Kröger, N. van Zandwijk and H. Bartelink	615	The need for immediate monitoring of treatment parameters and uniform assessment of patient data in clinical trials
S. Tsutsui, H. Kuwano, M. Mori, H. Matsuura and K. Sugimachi	620	Comparison of cell nuclear DNA contents between intraepithelial and invasive components of oesophageal squamous cell carcinoma
S. J. Proctor, P. Taylor, P. Donnan, *et al.*	624	A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis
A. Laquerriere, G. Raguenez-Viotte, M. Paraire, J.-P. Bizzari, M. Paresy, J.-P. Fillastre and J. Hemet	630	Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical, morphological and flow cytometry studies
H. R. Haak, K. M. J. Caekebeke-Peerlinck, A. P. van Seters and E. Briët	638	Prolonged bleeding time due to mitotane therapy
L. J. Vatten, O. P. Foss and S. Kvinnsland	641	Overall survival of breast cancer patients in relation to preclinically determined total serum cholesterol, body mass index, height and cigarette smoking: a population-based study
C. M. Ausiello, C. Palma, A. Maleci, G. C. Spagnoli, C. Amici, G. Antonelli, C. U. Casciani and A. Cassone	646	Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients
A. Turkes, J. P. Nott and K. Griffiths	650	Prostate-specific antigen: problems in analysis

Feature Articles

S. Monfardini and B. Chabner	653	Joint NCI–EORTC consensus meeting on neoplasia in the elderly
T. Bourne, K. Reynolds and S. Campbell	655	Ovarian cancer screening
G. Giles, H. Farrugia and B. Silver	659	Cancer registration in Victoria, Australia, 1982–1987

News	663	

Book Review

F. Bozzetti	667	*Surgical Oncology, Current Concepts and Practice* by C. S. McArdle

Letters

P. Fragu, M.-C. Fabri, S. Papadopoulos, S. Halpern, M. Prade and P. Rougier	668	*In vivo* drug intracellular localisation by analytical ion microscopy: preliminary study in gastric adenocarcinomas treated with 5-fluorouracil
P. K. Heinonen	669	Vitamin A, gonadotropins and ovarian cancer
M. C. Cercato, G. La Ferla, N. Pericoli, *et al.*	670	Cardiac tamponade as the initial manifestation of an extracardiac malignancy
Y. Bastion, B. Coiffier, J. D. Tigaud, D. Espinouse and P. A. Bryon	671	Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukaemia
D. Peest, R. Coldewey and H. Deicher for the German Myeloma Treatment Group	672	Overall vs. tumour-related survival in multiple myeloma
G. C. Wishart, J. A. Plumb, D. A. Spandidos and D. J. Kerr	673	H-*ras* transfection in mink lung epithelial cells may induce "atypical" multidrug resistance

P. S. G. J.Hupperets, G. P. M. ten Velde, H. Bron, L. Schouten and G. H. Blijham	674	A phase II study of vindesine plus etoposide in metastatic non-small cell lung cancer
J. Morris	675	Outcome following treatment for head and neck cancer: beyond clinical assessment

NUMBER 6

Comments and Critique

D. F. Bajorin and G. J. Bosl	677	Continued refinement in the treatment of germ cell tumour patients
V. Mahadevan and I. R. Hart	679	Tumour angiogenesis and metastasis
J. P. Neijt	680	Ovarian cancer treatment: time for some hard thinking
L. Parker and A. W. Craft	682	Neuroblastoma screening: more questions than answers?

Papers

D. P. Dearnaley, A. Horwich, R. A'Hern, J. Nicholls, G. Jay, W. F. Hendry and M. J. Peckham	684	Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up
S. J. Harland, L. A. Gumbrell and A. Horwich	691	Carboplatin dose in combination chemotherapy for testicular cancer
R. L. H. Jansen, R. Sylvester, D. T. Sleyfer, W. W. ten Bokkel Huinink, S. B. Kaye, W. G. Jones, J. Keizer, A. T. van Oosterom, S. Meyer, C. P. J. Vendrik, M. de Pauw and G. Stoter	695	Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery
T. Yashiro, T. Tsushima, H. Murakami, T. Obara, Y. Fujimoto, K. Shizume and K. Ito	699	Insulin-like growth factor-II (IGF-II)/mannose-6-phosphate receptors are increased in primary human thyroid neoplasms
W. Liebrich, P. Schlag, M. Manasterski, B. Lehner, M. Stöhr, P. Möller and V. Schirrmacher	703	*In vitro* and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients

Specialist Interest Articles

R. A. McClelland, D. Wilson, R. Leake, P. Finlay and R. I. Nicholson	711	A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification
S. Romain, C. Dussert and P. M. Martin	715	Determination of oestrogen receptors: application of the Passing–Bablock linear regression technique for comparison of enzyme immunoassay and radioligand binding assay in 1841 breast cancer tumours
C. Goerg and W.-B. Schwerk	720	Malignant ascites: sonographic signs of peritoneal carcinomatosis
F. Crippa, G. L. Buraggi, E. Di Re, M. Gasparini, E. Seregni, S. Canevari, M. Gadina, M. Presti, A. Marini and E. Seccamani	724	Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody
K. Mori, Y. Saitou, K. Tominaga, K. Yokoi and N. Miyazawa	729	Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin
L. Th. Vlasveld, M. P. W. Gallee, S. Rodenhuis and B. G. Taal	732	Intraperitoneal chemotherapy for malignant peritoneal mesothelioma
M. de Forni, S. Lachau, F. Huguet, P. Canal, G. Laurent, C. Chevreau, H. Roche and R. Bugat	735	Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases
C. K. van Kalken, J. J. M. van der Hoeven, J. de Jong, G. Giaccone, G. J. Schuurhuis, P. A. Maessen, W. M. D. Blokhuis, W. J. F. van der Vijgh and H. M. Pinedo	739	Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients
Y. Monden, T. Uyama, S. Kimura and T. Taniki	745	Extrathymic malignancy in patients with myasthenia gravis
A. T. van Oosterom, W. W. ten Bokkel Huinink, M. E. L. van der Burg, J. B. Vermorken, P. H. B. Willemse and J. P. Neijt	747	Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer
F. Mandelli, M. C. Petti, A. Ardia, N. Di Pietro, F. Di Raimondo, F. Ganzina, E. Falconi, E. Geraci, S. Ladogana, R. Latagliata, C. Malleo, F. Nobile, N. Petti, B. Rotoli, G. Specchia, A. Tabilio and L. Resegotti	750	A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia
D. J. Th. Wagener, P. H. M. de Mulder, J. Th. Burghouts and J. J. Croles	755	Phase II trial of cisplatin for adenocarcinoma of unknown primary site

C. Uderzo, A. Rovelli, M. Bonomi, L. Fomia, L. Pirovano and G. Masera	758	Total parenteral nutrition and nutritional assessment in leukaemic children undergoing bone marrow transplantation
H. Naito, N. Kuzumaki, J.-i. Uchino, R. Kobayashi, T. Shikano, Y. Ishikawa and S. Matsumoto	762	Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription–polymerase chain reaction
J. C. Murray, K. A. Smith and D. M. Stern	765	Flavone acetic acid potentiates the induction of endothelial procoagulant activity by tumour necrosis factor
B. Theisinger, C. Welter, G. Seitz, M.-C. Rio, R. Lathe, P. Chambon and N. Blin	770	Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma
X. F. Hu, G. Nadalin, M. De Luise, T. J. Martin, A. Wakeling, R. Huggins and J. R. Zalcberg	773	Circumvention of doxorubicin resistance in multi-drug resistant human leukaemia and lung cancer cells by the pure antioestrogen ICI 164384
A. L. Zietman, H. D. Suit, P. G. Okunieff, S. M. Donnelly, S. Dieman and S. Webster	778	The life shortening effects of treatment with doxorubicin and/or local irradiation on a cohort of young C3Hf/Sed mice

Feature Articles

R. Bicknell and A. L. Harris	781	Novel growth regulatory factors and tumour angiogenesis
G. Terenghi and J. M. Polak	785	Morphological studies using *in situ* hybridisation
H. Zwierzina	789	Meeting report: first meeting of the "Task Force Cytokines" of the EORTC Research Branch
P. G. Isaacson	795	Recent advances in the biology of lymphomas
News	802	

Letters

R. P. de Dycker, R. L. A. Neumann, T. Schumacher and U. Heckmann	804	Sequential proleukin (rIL-2) by continuous infusion with cisplatin and cyclophosphamide in patients with unresectable ovarian cancer
L. Canobbio, F. Boccardo, D. Guarneri, C. Calabria, A. Decensi, A. Curotto, G. Martorana and L. Giuliani	804	Phase II study of navelbine in advanced renal cell carcinoma
M. J. Millward and B. M. J. Cantwell	806	Development of breast cancer during long-term tamoxifen therapy for lymphangioleiomyomatosis
A. R. Dixon, L. Jackson, J. F. R. Robertson, R. I. Nicholson and R. W. Blamey	806	Combined goserelin and tamoxifen in premenopausal advanced breast cancer: duration of response and survival
B. A. Stoll	808	High risk breast cancer in young women
H. H. Gerhartz and H. Schmetzer	809	Minimal residual disease in acute leukaemia
E. M. Pogliani, L. Borin, C. G. Passerini, C. Lanzafame and G. Corneo	810	Early detection of relapse in acute non-lymphoblastic leukaemia patients by cancer procoagulant assay
U. Tirelli, V. Zagonel and S. Monfardini	811	Common errors in conducting and reporting clinical trials in non-Hodgkin lymphomas and patients' age
G. Lugassy, A. Shapira, E. Dukatch and A. Berrebi	812	Chronic lymphocytic leukaemia in 2 young adults
J. Saito, M. Inoue, C. Azuma, F. Saji and O. Tanizawa	813	Histogenetic analysis of ovarian teratomas by DNA fingerprinting

NUMBER 7

Comments and Critique

C. Hill and A. Laplanche	815	Cancer mortality around nuclear sites
M. H. Cullen	817	Dose-response relationships in testicular cancer
M. Viot and J. Klastersky	818	Prophylaxis and empiric therapy for streptococcal infections in febrile neutropenic patients
K. MacRae	819	Patients excluded from entry to clinical trials

Papers

J. M. Richard, A. Kramar, R. Molinari, J. L. Lefebvre, F. Blanchet, A. Jortay and H. Sancho-Garnier	821	Randomised EORTC Head and Neck Cooperative Group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma

J. Cockburn, D. Hill, L. Irwig, T. De Luise, D. Turnbull and P. Schofield	827	Development and validation of an instrument to measure satisfaction of participants at breast screening programmes
J. P. Droz, J. L. Pico, M. Ghosn, A. Gouyette, D. Baume, G. Piot, M. Ostronoff, C. Theodore, F. Beaujean and M. Hayat	831	Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer
A. De Rossi, F. Mammano, A. Del Mistro and L. Chieco-Bianchi	835	Serological and molecular evidence of infection by human T-cell lymphotropic virus type II in Italian drug addicts by use of synthetic peptides and polymerase chain reaction

Specialist Interest Articles

G. V. Bogliolo, R. Lerza, G. B. Bottino, M. P. Mencoboni, I. M. Pannacciulli, M. Vannozzi, R. A. Fulco, F. Merlo and M. Esposito	839	Regional pharmacokinetic selectivity of intrapleural cisplatin
G. J. Ossenkoppele, P. W. Wijermans, J. J. P. Nauta, P. C. Huijgens and M. M. A. C. Langenhuijsen	842	Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: *in vivo* and *in vitro* cytotoxicity
M. Dowsett, A. Mehta, B. M. J. Cantwell and A. L. Harris	846	Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion
J. Bonneterre, P. Kerbrat, P. Fargeot, R. Metz, H. Roche, P. Bastit, A. Chevrier, M. Tubiana-Hulin, G. Geyer and P. Cappelaere	849	Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer
M. Frenay, B. Giroux, S. Khoury, J. M. Derlon and M. Namer	852	Phase II study of fotemustine in recurrent supratentorial malignant gliomas
H. Gamm, A. Lindemann, R. Mertelsmann and F. Herrmann	856	Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy
F. Calero, E. Asins-Codoñer, J. Jimeno, F. Rodriguez Escudero, J. Mendaña, J. Iglesias, F. Matía, A. Armas, R. Díaz-Castellanos and J. Garzón	864	Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO)
A. L. Jones, J. Holborn, S. Ashley and I. E. Smith	866	Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide
D. M. Tillman, T. Aitchison, D. C. Watt and R. M. MacKie	870	Stage II melanoma in the west of Scotland, 1976–1985: prognostic factors for survival
P. K. Lipponen, M. J. Eskelinen and S. Nordling	877	Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S-phase fraction and DNA ploidy
A. Riccardi, M. Giordano, M. Danova, M. Girino, S. Brugnatelli, G. Ucci and G. Mazzini	882	Cell kinetics with *in vivo* bromodeoxyuridine and flow cytometry: clinical significance in acute non-lymphoblastic leukaemia
M. J. Trotter, D. J. Chaplin and P. L. Olive	887	Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma
L. Matturri, B. Biondo, F. Uggeri and A. M. Lavezzi	893	Densitometric evaluation of DNA content in colorectal cancer
Y. P. Keepers, P. E. Pizao, G. J. Peters, J. van Ark-Otte, B. Winograd and H. M. Pinedo	897	Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for *in vitro* chemosensitivity testing
K. Overvad, D. Y. Wang, J. Olsen, D. S. Allen, E. B. Thorling, R. D. Bulbrook and J. L. Hayward	900	Selenium in human mammary carcinogenesis: a case-cohort study
P. C. Billings, D. L. Brandon and J. M. Habres	903	Internalisation of the Bowman–Birk protease inhibitor by intestinal epithelial cells
R. I. Nicholson, N. Bouzubar, K. J. Walker, R. McClelland, A. R. Dixon, J. F. R. Robertson, I. O. Ellis and R. W. Blamey	908	Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation
D. R. Gordon, A. Venturini, M. Rosselli Del Turco, D. Palli and E. Paci	913	What healthy women think, feel and do about cancer, prevention and breast cancer screening in Italy
J. Williams, C. Clifford, J. Hopper and G. Giles	917	Socioeconomic status and cancer mortality and incidence in Melbourne

Feature Articles

S. J. Whitaker, S. N. Powell and T. J. McMillan	922	Molecular assays of radiation-induced DNA damage
M. McCredie, M. Coates, T. Churches and R. Taylor	928	Cancer incidence in New South Wales, Australia
E. G. Levine and D. Raghavan	932	Treatment of refractory testis cancer: salvage or savage chemotherapy?

EORTC Research Branch Scientific Advisory Board	936	Towards improved cancer diagnosis and treatment founded on current developments in the basic sciences: options for intensified European efforts
News	940	
Letters		
J. P. Kleisbauer, J. Vergeret, P. Balmes, M. Reynaud-Gaubert, A. Taytard, R. Targhetta, P. Thomas, F. Bonnaud and R. Poirier for the Groupe Français de Pneumo-Cancérologie (GFPC)	943	Phase II study of pirarubicin in untreated metastatic small cell lung carcinoma
O. Merimsky, M. Inbar and S. Chaitchik	944	Etoposide, doxorubicin and cisplatin in advanced or metastatic gastric cancer
R. E. Coleman, L. Y. Dirix, D. Dodwell, M. Tubiana-Hulin, J.-J. Body, R. Becher, G. K. White, R. D. Rubens, A. Van Oosterom, A. Howell and J. Ford	945	Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases
E. Orhon, I. Ulgenalp, I. Baser, S. Dilek and R. Pabuccu	946	Primary squamous cell carcinoma of the endometrium
M. Tonetti, C. Polvani, E. Zocchi, L. Guida, U. Benatti, P. Biassoni, F. Romei, A. Guglielmi, C. Aschele, A. Sobrero and A. De Flora	947	Liver targeting of autologous erythrocytes loaded with doxorubicin
E. Kosmas, A. Panayotou, S. Parastatides, A. Damianos, M. Komis, S. Michaelides, B. Baroutsou and V. Polychronopoulos	948	Neuron-specific enolase (NSE) in bronchial washings: a better diagnostic marker for small cell lung cancer

NUMBER 8

Comments and Critique		
M. Peckham	949	Three dimensions: cell and molecular oncology, clinical oncology and epidemiology
M. R. Price	949	*EJC* and EACR
P. J. Hoskin	950	Palliation of bone metastases
J. Crozemarie	951	Prevention conference overview
G. J. Graham and I. B. Pragnell	952	Treating cancer: the potential role of stem cell inhibitors
Papers		
V. J. Lewington, A.J. McEwan, D. M. Ackery, R. J. Bayly, D. H. Keeling, P.M. Macleod, A. T. Porter and M. A. Zivanovic	954	A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone
J. H. Olsen, P. de Nully Brown, G. Schulgen and O. M. Jensen	958	Parental employment at time of conception and risk of cancer in offspring
E. Engelsman, J. C. M. Klijn, R. D. Rubens, J. Wildiers, L. V. A. M. Beex, M. A. Nooij, N. Rotmensz and R. Sylvester	966	"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
G. Granata, D. Coradini, V. Cappelletti and G. Di Fronzo	970	Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers
Specialist Interest Articles		
G. Falkson, D. C. Tormey, P. Carey, R. Witte and H. C. Falkson	973	Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer
M. Toi, A. Osaki, H. Yamada and T. Toge	977	Epidermal growth factor receptor expression as a prognostic indicator in breast cancer
M. Sant, G. Gatta, A. Micheli, A. Verdecchia, R. Capocaccia, P. Crosignani and F. Berrino	981	Survival and age at diagnosis of breast cancer in a population-based cancer registry
E. T. Barron, P. P. A. Smyth, E. W. McDermott, I. N. Tobbia and N. J. O. Higgins	985	Quantitative cytochemistry of glucose-6-phosphate dehydrogenase in benign and malignant breast tumours
M. J. Eskelinen, P. K. Lipponen, Y. Collan and K. J. Syrjänen	989	The role of nucleolar organiser regions as prognostic factors in breast cancer
P. H. B. Willemse, J. G. Aalders, H. W. A. de Bruyn, N. H. Mulder, D. Th. Sleijfer and E. G. E. de Vries	993	CA-125 in ovarian cancer: relation between half-life, doubling time and survival

M. Gion, R. Dittadi, A. E. Leon, G. Bruscagnin, D. Pelizzola, G. Giovannini, M. Giganti, G. Messeri, M. Quercioli, E. Flamini, A. Riccobon, C. Bozzetti, M. Benecchi, M. De Lena, A. Paradiso, G. Ruggeri, P. Luisi and A. Piffanelli	996	Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: a multicentre study
M. J. Harding, L. J. McNulty, J. Paul, F. Lee, A. Brown and M. Soukop	1002	Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease
J. D. Borsi, F. Wesenberg, T. Stokland and P. J. Moe	1006	How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia
K. Hayat, S. Rodgers, L. Bruce, R. C. Rees, K. Chapman, S. Reeder, M. S. Dorreen, E. Sheridan, T. Sreenivasan and B. W. Hancock	1009	Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2
P. Lissoni, E. Tisi, F. Brivio, S. Barni, F. Rovelli, M. Perego and G. Tancini	1014	Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2
C.-D. Schiller, A. Gescher and P. Jheeta	1017	Mechanism of toxicity of the antimelanoma drug 4-hydroxyanisole in mouse hepatocytes
F. de Miguel, R. García-Cañero and P. Esbrit	1022	Co-purification of calcium transport-stimulating and DNA synthesis-stimulating agents with parathormone-like activity isolated from the hypercalcaemic strain of the Walker 256 tumour
J.-L. Merlin	1026	Encapsulation of doxorubicin in thermosensitive small unilamellar vesicle liposomes
J.-L. Merlin	1031	*In vitro* evaluation of the association of thermosensitive liposome-encapsulated doxorubicin with hyperthermia
P.-H. Chang, S. Pervaiz, M. Battaglino, J. L. Matthews, C. Clark, J. Day, J. Preskitt, D. Vanderpool and K. S. Gulliya	1034	Synergy between preactivated photofrin-II and tamoxifen in killing retrofibroma, pseudomyxoma and breast cancer cells
J. Hansson, A. M. J. Fichtinger-Schepman, M. Edgren and U. Ringborg	1039	Comparative study of two human melanoma cell lines with different sensitivities to mustine and cisplatin
E. Shimizu, Y. Nakamura, J.-n. Mukai, K. Tani, T. Yamashita, F. Hojo, Y. Hashimoto and T. Ogura	1046	Pharmacokinetics of bronchial artery infusion of mitomycin in patients with non-small cell lung cancer

Feature Articles

I. Pleško, E. Kramárová, V. Vlasák and A. Obšitníková	1049	Development of registration and cancer incidence rates and trends in Slovakia
S. Petrasch, H. Stein, M. H. Kosco and G. Brittinger	1052	Follicular dendritic cells in non-Hodgkin lymphomas: localisation, characterisation and pathophysiological aspects
V. Beral, H. Jaffe and R. Weiss	1057	Cancer surveys: cancer, HIV and AIDS

Book Review

A. L. Baert	1058	*Interventional Radiology* by R. F. Dondelinger *et al.*, eds

News 1058

Letters

D. Bissett, S. B. Kaye and D. J. Kerr	1060	Can primary osteosarcoma act as a third space after high-dose methotrexate?
P. Jacobs, G. S. Rutherford, H. S. King and M. Vincent	1061	Methotrexate encephalopathy
R. E. Coleman, C. J. Twelves, S. M. O'Reilly, R. D. Rubens, M. A. Richards and P. G. Harper	1062	Influence of dexamethasone dose on the control of chemotherapy-induced nausea and vomiting
R. Erttmann, M. Münchmeyer, G. Looft and K. Winkler	1064	Conserved cytostatic activity of aclarubicin in a doxorubicin selected friend leukaemia cell line with multifactorial multidrug resistance
S. Monfardini, U. Tirelli, D. Serraino and I. Fentiman	1065	After 65, cancer has a different impact on life expectancy in men and women
O. Merimsky, M. Inbar, I. Reider-Groswasser and S. Chaitchik	1066	Fotemustine with or without dacarbazine for brain metastases of malignant melanoma
S. M. Crawford	1067	Growth rate of metastatic non-seminomatous germ cell testicular tumours
P. Price, S. J. Hogan and A. Horwich	1067	Growth rate of metastatic non-seminomatous germ cell testicular tumours—a reply

NUMBER 9

Comments and Critique

K. Sikora 1069 Gene therapy for cancer

V. C. Jordan 1070 Are we giving tamoxifen for too long?

D. Raghavan 1072 Clinician surrogates and equipoise: an analogy to lawyers who represent themselves?

Papers

G. Berglund, C. Bolund, T. Fornander, L. E. Rutqvist and P.-O. Sjödén 1075 Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients

J. Lemerle, D. Amaral, D. P. Southall, J. Upward and R. D. Murdoch 1081 Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients

J. H. Turner and P. G. Claringbold 1084 A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate

Specialist Interest Articles

N. Aass, S. D. Fosså, L. Theodorsen and N. Norman 1087 Prediction of long-term gonadal toxicity after standard treatment for testicular cancer

S. Kaasa, N. Aass, A. Mastekaasa, E. Lund and S. D.Fosså 1091 Psychosocial well-being in testicular cancer patients

K. S. Oláh, H. Gee, S. Blunt, J. A. Dunn, K. Kelly and K. K. Chan 1095 Retrospective analysis of 318 cases of uterine sarcoma

A. Decensi, D. Guarneri, M. C. Paoletti, J. M. Lalanne, F. Merlo and F. Boccardo for the Italian Prostatic Cancer Project (PONCAP) 1100 Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer

V. Iberti, M. Donadio and G. Giaccone 1104 Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer

A. von Rohr, H. Anderson, R. McIntosh and N. Thatcher 1106 Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer

B. T. Sørensen, K. Nielsen, S. Steenholdt, H. Schultz and A. Jakobsen 1109 Treatment of extensive small cell lung cancer with carboplatin and teniposide

T. C. Kok, A. van der Gaast, T. A. W. Splinter and H. W. Tilanus for the Rotterdam Esophageal Tumor Study Group 1112 Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal–gastric junction area

S. Fujimoto, H. Furue, T. Kimura, T. Kondo, K. Orita, T. Taguchi, K. Yoshida and N. Ogawa 1114 Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study

W. Graf, B. Glimelius, L. Påhlman and R. Bergström 1119 Determinants of prognosis in advanced colorectal cancer

P. Pasqualetti, R. Casale, A. Collacciani and D. Colantonio 1123 Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features

N. Rotmensz, G. De Palo, F. Formelli, A. Costa, E. Marubini, T. Campa, A. Crippa, G. M. Danesini, M. Delle Grottaglie, M. G. Di Mauro, A. Filiberti, M. Gallazzi, A. Guzzon, A. Magni, W. Malone, L. Mariani, M. Palvarini, M. Perloff, M. Pizzichetta and U. Veronesi 1127 Long-term tolerability of fenretinide (4-HPR) in breast cancer patients

L. C. G. Verhoef, L. J. A. Stalpers, A. L. M. Verbeek, T. Wobbes and W. A. J. van Daal 1132 Breast-conserving treatment or mastectomy in early breast cancer: a clinical decision analysis with special reference to the risk of local recurrence

N. W. Marschner, M. Adler, G. A. Nagel, D. Christmann, E. Fenzl and B. Upadhyaya 1137 Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide

Y. Kano, M. Akutsu, T. Kasahara and S. Sakamoto 1141 Schedule-dependent synergism and antagonism between methotrexate and 6-mercaptopurine in a human acute lymphoblastic cell line

T. Zaccheo, D. Giudici, G. Ornati, A. Panzeri and E. di Salle 1145 Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours

H. S. Reinhold, A. E. van den Berg-Blok and A. P. van den Berg 1151 Dose-effect relationships for glucose-induced tumour acidification and its erythrocyte flux

V. Cappelletti, C. Ruedl, G. Granata, D. Coradini, G. Del Bino and G. Di Fronzo	1154	Interaction between hormone-dependent and hormone-independent human breast cancer cells
N. K. Farzaneh, T. L. Walden, V. J. Hearing and D. M. Gersten	1158	B700, an albumin-like melanoma-specific antigen, is a vitamin D binding protein
Feature Articles		
G. Schwartsmann, J. Wanders, I. J. Koier, H. R. Franklin, O. Dalesio, H. W. Hornstra, M. van Glabbeke, J. Renard, A. T. Van Oosterom, S. B. Kaye and H. M. Pinedo	1162	EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents
R. T. D. Oliver	1168	New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer
P. A. Riley	1172	Melanogenesis: a realistic target for antimelanoma therapy?
News	1178	
Letters		
O. Mogensen	1180	Tumour-associated trypsin inhibitor and CA-125 during treatment of mucinous ovarian cancer in 2 patients
L. Babilonti, P. Tenti, S. Tateo and C. Zara	1181	Missed diagnoses revealed at necropsy in patients with gynaecological malignancies
S. N. Udintsev and V. P. Schakhov	1182	Decrease of cyclophosphamide haematotoxicity by *Rhodiola rosea* root extract in mice with Ehrlich and Lewis transplantable tumours
H. T. Hassan	1182	*In vitro* interaction between retinoids and cytokines in human myeloid leukaemia cells
U. Tirelli, T. Troiano, M. Spina, E. Vaccher, D. Errante, I. M. Crosato and S. Monfardini	1184	Skin carcinoma in 2 patients with HIV infection
C. Davis	1185	Meningiomas and sex hormones, radiotherapy and benign brain tumours
D. Howel	1185	Comparison of prostate-specific antigen assays
M. Reinfuss, D. Kociołek and J. Skołyszewski	1186	Adult Wilms' tumour
J. M. Lopes, M. E. Paiva, E. Ferreira, C. Lopes and M. Sobrinho-Simões	1187	Round cell sarcoma after clear cell sarcoma remission
O. Merimsky, M. Inbar, I. Reider-Groswasser, M. Scharf and S. Chaitchik	1188	Ifosfamide-related acute encephalopathy: clinical and radiological aspects
J. H. Anderson, J. A. Goldberg, J. G. Eley, T. L. Whateley, D. J. Kerr, T. G. Cooke and C. S. McArdle	1189	A phase I study of regionally administered mitomycin microcapsules for patients with colorectal liver metastases
Correction	1190	

NUMBER 10

Comments and Critique		
M.Goddard and M. Drummond	1191	The economic evaluation of cancer treatments and programmes
J. B. Trimbos	1196	Treatment of early ovarian cancer
I. R. Judson	1198	Phase II studies: wrong doses, wrong patients?
Specialist Interest Articles		
F. d'Amore, B. E. Christensen, H. Brincker, N. T. Pedersen, K. Thorling, J. Hastrup, M. Pedersen, M. K. Jensen, P. Johansen, E. Andersen, B. Bach and E. Sørensen on behalf of the Danish LYFO Study Group	1201	Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas
C. I. Falkson, H. C. Falkson and G. Falkson	1208	Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer

S. Chiara, S. Mammoliti, C. Oliva, L. Merlini, M. Bruzzone, M. R. Sertoli, G. C. Parodi, N. Ragni, G. Foglia, F. Odicino, G. Parodi, L. Iskra, F. Carnino, E. Guercio, P. F. Conte and R. Rosso	1211	Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience
P. Fragu, F. Lemarchand-Venencie, S. Benhamou, P. François, D. Jeannel, E. Benhamou, I. Sezary-Lartigau and M.-F. Avril	1215	Long-term effects in skin and thyroid after radiotherapy for skin angiomas: a French retrospective cohort study
H. M. Oosterkamp, L. Th. Vlasveld, J. Wanders, J. H. Beijnen, O. van Tellingen, A. C. Dubbelman, G. P. C. Simonetti, H. R. Franklin, J. B. Vermorken and W. W. Ten Bokkel Huinink	1222	Phase I study of vintriptol, a tryptophan ester of vinblastine
Ph. Rougier, M. Ducreux, J. P. Pignon, D. Elias, J. M. Tigaud, J. Lumbroso, P. Ruffie and P. H. Lasser	1226	Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy
A. Martoni, B. Melotti, M. Guaraldi and F. Pannuti	1231	Activity of high-dose epirubicin in advanced non-small cell lung cancer
H. Anderson, J. H. Scarffe, M. Ranson, A. G. Kamthan, M. Dougal, S. A. Russell, M. J. S. Wilkinson and D. G. Ostick	1234	MMAF for advanced gastric cancer
M. Riggi, P. Ruffie, S. Voisin, I. Monnet, H. de Cremoux, J. C. Saltiel, M. Martin, L. Vergne, J. Huet and E. Cvitkovic for ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)	1238	Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer
O. R. Leeuwenkamp, J. P. Neijt, W. J. F. van der Vijgh and H. M. Pinedo	1243	Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate
A. Hajri, C. Bruns, P. Marbach, M. Aprahamian, D. S. Longnecker and C. Damgé	1247	Inhibition of the growth of transplanted rat pancreatic acinar carcinoma with octreotide
R. Talamini, G. Boz, S. Franceschi, G. Franchin and M. G. Trovò	1253	Evaluation of hospital care in a radiotherapy department in north-eastern Italy
H. Yamaue, H. Tanimura, T. Tsunoda, M. Tani, M. Iwahashi, K. Noguchi, M. Tamai, T. Hotta and K. Arii	1258	Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay
M. G. Thompson and J. A. Hickman	1263	Doxorubicin interactions at the membrane: evidence for a biphasic modulation of inositol lipid metabolism
R. Kiss, I. Salmon, O. Pauwels, S. Gras, A. Danguy, C. Etievant, J.-L. Pasteels and J. Martinez	1268	*In vitro* influence of gastrin, oestradiol and gonadotropin-releasing hormone on HCT-15 and LoVo human colorectal neoplastic cell proliferation
B. F. A. M. van der Laan, G. Jansen, I. Kathmann, J. H. Schornagel and G. J. Hordijk	1274	Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules
B. Pålsson, Å. Andren-Sandberg and P. Masson	1279	Plasma concentrations of CA-50 in relation to tumour burden in exocrine pancreatic cancer
T. Westin, H. Zachrisson, S. Edström and K. Lundholm	1282	Ornithine decarboxylase activity in mouse tumour tissue in response to refeeding and diet components
K. G. Engström , K. Grankvist and R. Henriksson	1288	Early morphological detection of estramustine cytotoxicity measured as alteration in cell size and shape by a new technique of microperifusion
D. F. C. Gibson, S. A. Roberts and G. S. Evans	1295	Changes in the hormone dependency of epithelial cell proliferation in the genital tract of mice following neonatal oestrogen treatment
M.-L. Lacombe, X. Sastre-Garau, I. Lascu, A. Vonica, V. Wallet, J. P. Thiery and M. Véron	1302	Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumours
B. Dutrillaux, M. Gerbault-Seureau, B. Zafrani and M. Prieur	1307	Prolonged G2 phase of breast cancer cells and chromosome damage
E. H. Åvall Lundqvist, K. Sjövall and P. H. E. Eneroth	1313	Initial experiences with serum alkaline DNase activity in monitoring the effects of therapy for carcinoma of the uterine cervix
A. van der Heijden, A. Twijnstra, W. P. M. A. Lamers, P. S. G. J. Hupperets and G. Freling	1315	An unusual cause of diplopia in a cancer patient

Feature Articles

R. M. MacKie, A. Osterlind, D. Ruiter, P. Fritsch, M. Aapro, J.-P. Cesarini, R. Vanwijck, K. Drzewiecki, K. Kolmel and C. Muir — 1317 — Report on Consensus Meeting of the EORTC Melanoma Group on Educational Needs for Primary and Secondary Prevention of Melanoma in Europe

T. P. Mäkelä, K. Mattson and K. Alitalo — 1323 — Tumour markers and oncogenes in lung cancer

Book Reviews

P. Scalliet — 1328 — *The Physics and Radiobiology of Fast Neutron Beams* by D. K. Bewley

C. W. Imrie — 1328 — *Cancer of the Pancreas* by J. P. Neoptolemus, ed.

News — 1329

Letters

I. Mittra — 1331 — Consensus guidelines and clinical practice in breast cancer

T. Brutel de la Rivière, F. B. J. M. Thunnissen and G. P. M. ten Velde — 1332 — Unusual clinical presentation of bronchioloalveolar carcinoma in 2 cases

S. M. Di Stasi, A. Tabilio, G. Virgili, G. Vespasiani, M. Porena and F. Micali — 1333 — Intralesional recombinant α_{2a} interferon therapy in superficial transitional cell carcinoma of the bladder

S. Daugaard, U. Hørding and T. Schiødt — 1334 — Ewing's sarcoma and Epstein–Barr virus

B. M. O'Connor, P. Ziegler and M. B. Spaulding — 1334 — Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer

A. Mijović, A. Mijović, L. Medenica and Z. Rolović — 1336 — Sweet's syndrome in chronic phase of chronic myeloid leukaemia

N. Hu, S. M. Dawsey, M. Wu and P. R. Taylor — 1336 — Family history of oesophageal cancer in Shanxi Province, China

Y. Touitou, A. Bogdan and B. Dautzenberg — 1337 — Specificity of tumour marker antigens in benign respiratory diseases

E. May and B. Allolio — 1338 — Fatal toxic epidermal necrolysis during suramin therapy

K. Holli and M. Hakama — 1338 — Terminal stages of breast cancer: changes in clinical practice

Correction — 1339

NUMBER 11

Comments and Critique

M. Peckham — 1341 — *EJC* expands: *Oral Oncology*

C. Scully — 1341 — *Oral Oncology*

K. E. Hellström and P. D. Senter — 1342 — Activation of prodrugs by targeted enzymes

A. de Ruiter and A. Mindel — 1343 — Anal intraepithelial neoplasia

F. X. Bosch and E. Cardis — 1345 — Black tobacco and cancer: introducing an epidemiological review

P. Ryan — 1348 — Smoking and commercial airline flights in Europe

J. S. Tobias and S. G. Bown — 1350 — Palliation of malignant obstruction—use of lasers and radiotherapy in combination

Papers

J. Wallner, D. Depisch, M. Hopfner, K. Haider, J. Spona, H. Ludwig and R. Pirker — 1352 — *MDR*1 gene expression and prognostic factors in primary breast carcinomas

R. J. Ott, M. Brada, M. A. Flower, J. W. Babich, S. R. Cherry and B. J. Deehan — 1356 — Measurements of blood–brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma

C. J. Springer, K. D. Bagshawe, S. K. Sharma *et al.* — 1361 — Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds

J. P. Neijt, W.W. ten Bokkel Huinink, M. E. L. van der Burg *et al.* — 1367 — Long-term survival in ovarian cancer

M. Tateishi, T. Ishida, T. Mitsudomi, S. Kaneko and K. Sugimachi — 1372 — Prognostic value of c-*erb*B-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma

Specialist Interest Articles

J. A. Gietema, P. H. B. Willemse, N. H. Mulder, J. Oldhoff, E. G. E. de Vries and D. Th. Sleijfer	1376	Alternating cycles of PVB and BEP in the treatment of patients with advanced seminoma
Ph. Rougier, J. Oliveira, M. Ducreux, C. Theodore, J. Kac and J. P. Droz	1380	Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin
R. de Wit, M. Tesselaar, T. C. Kok, C. Seynaeve, C. J. Rodenburg, J. Verweij, P. A. Helle and G. Stoter	1383	Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer
P. V. Hansen, K. Glavind, J. Panduro and M. Pedersen	1385	Paternity in patients with testicular germ cell cancer: pretreatment and post-treatment findings
S. Viviani, G. Ragni, A. Santoro *et al.*	1389	Testicular dysfunction in Hodgkin's disease before and after treatment
P. Correale, P. Tagliaferri, L. Celio, G. Genua, S. Montagnani and A. R. Bianco	1393	Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity *in vitro*
V. Sacchini, A. Luini, S. Tana *et al.*	1395	Quantitative and qualitative cosmetic evaluation after conservative treatment for breast cancer
A. Riccardi, P. G. Gobbi, G. Ucci, D. Bertoloni, R. Luoni, L. Rutigliano and E. Ascari	1401	Changing clinical presentation of multiple myeloma
P. M. J. McSheehy, M. Gervasoni, V. Lampasona, E. Erba and M. D'Incalci	1406	Studies of the differentiation properties of camptothecin in the human leukaemic cells K562
S. A. Narod, D. W. Thompson, M. Jain, C. Wall, L. M. Green and A. B. Miller	1411	Dysplasia and the natural history of cervical cancer: early results of the Toronto cohort study
C. Pedersen, J. Gerstoft, J. D. Lundgren *et al.*	1416	HIV-associated lymphoma: histopathology and association with Epstein–Barr virus genome related to clinical, immunological and prognostic features
W. R. Bezwoda, T. Golombick, R. Dansey and J. Keeping	1423	Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy *in vivo* and *in vitro*
E. Boven, H. J. Haisma, H. Bril *et al.*	1430	Tumour localisation with ^{131}I-labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patients
Y. Tokue, Y. Saijo, K. Satoh and M. Motomiya	1436	Increased levels of mitochondrial DNA in an etoposide-resistant human monocytic leukaemia cell line (THP-1/E)
O. Merimsky, M. Inbar, M. Hareuveni, B. Witenberg, Y. Wolman and S. Chaitchik	1440	Serial serum MCA measurements in the follow-up of breast cancer patients
B. Casslén, B. Gustavsson and B. Åstedt	1445	Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours
W. T. Smith, M. H. N. Tattersall, L. M. Irwig and A. O. Langlands	1448	Undergraduate education about cancer
T. W. A. Huisman, H. L. J. Tanghe, J. W. Koper *et al.*	1453	Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics
W. N. Scott, P. Mullen and W. R. Miller	1458	Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone
G. Schlimok, I. Funke, K. Pantel, F. Strobel, F. Lindemann, J. Witte and G. Riethmüller	1461	Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance

---

Feature Articles

C. Hélène	1466	Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides
A. Woodward and A. J. McMichael	1472	Passive smoking and cancer risk: the nature and uses of epidemiological evidence
A. Costa and V. C. Jordan	1479	Meeting report: Long-term antihormonal therapy for breast cancer
C. K. van Kalken, H. M. Pinedo and G. Giaccone	1481	Multidrug resistance from the clinical point of view
F. E. Alexander, T. J. Ricketts, P. A. McKinney and R. A. Cartwright	1486	Community lifestyle characteristics and lymphoid malignancies in young people in the UK
P. Vineis	1491	Black (air-cured) and blond (flue-cured) tobacco and cancer risk I: bladder cancer
J. H. Scarffe	1493	Emerging clinical uses for GM-CSF

P. Boffetta, E. Cardis, H. Vainio *et al.*	1504	Cancer risks related to electricity production
J. R. McLaughlin, N. Kreiger, L. D. Marrett and E. J. Holowaty	1520	Cancer incidence registration and trends in Ontario
R. C. Stein, S. Cannon, A. Cassoni, J. S. Pringle, D. J. Stoker and R. L. Souhami	1525	Clinical oncology: case presentations from oncology centres 1. Ewing's sarcoma
Book Review		
C. Berry	1533	*Autopsy in Epidemiology and Medical Research* by E. Riboli and M. Delendi
News	1534	

NUMBER 12

Comments and Critique		
G. Gahrton	1537	Bone marrow transplantation with unrelated volunteer donors
J. M. Kurtz	1539	Should surgery remain the initial treatment of "operable" breast cancer?
K. Mross	1542	New anthracycline derivatives: what for?
J. Festen	1544	Lung cancer therapy in the elderly
M. Brada	1545	Radiosurgery for brain tumours
S. P. Hauser	1549	Unproven methods in oncology
Papers		
J. L. Mansi, D. Easton, U. Berger, J.-C. Gazet, H. T. Ford, D. Dearnaley and R. C. Coombes	1552	Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up
S. Aaltomaa, P. Lipponen, M. Eskelinen, V.-M. Kosma, S. Marin, E. Alhava and K. Syrjänen	1555	Prognostic factors in axillary lymph node-negative (pN–) breast carcinomas
R. Corbett, J. Olliff, N. Fairley, J. Moyes, J. Husband, R. Pinkerton, R. Carter, J. Treleaven, T. McElwain and S. Meller	1560	A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scinitigraphy and marrow histology/cytology in neuroblastoma
M. A. Rosenthal, C. A. Bull, A. S. Coates, G. Stevens, W. H. McCarthy, H. Mameghan and R. F. Kefford	1564	Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma
M. H. Robinson, L. Spruce, R. Eeles, I. Fryatt, C. L. Harmer, J. M. Thomas and G. Westbury	1567	Limb function following conservation treatment of adult soft tissue sarcoma
I. Mittra and K. D. MacRae	1574	A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology?
H. von der Maase, P. Geertsen, N. Thatcher, C. Jasmin, A. Mercatello, S. D. Fosså, M. Symann, G. Stoter, G. Nagel, L. Israel, R. Oskam, P. Palmer and C. R. Franks	1583	Recombinant interleukin-2 in metastatic renal cell carcinoma—a European multicentre phase II study
P. J. O'Dwyer, C. J. Langer, J. Walczak, M. H. Levy, K. Padavic-Shaller, G. R. Hudes, S. Litwin and R. L. Comis	1589	Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer
J. Lokich, C. Moore, N. Anderson and M. Bern	1593	Infusion of floxuridine plus etoposide plus cisplatin in human malignancies
M. P. N. Findlay, A.-M. Griffin, D. Raghavan, K. E. McDonald, A. S. Coates, P. J. Duval and P. Gianoutsos	1597	Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means?
F. Villani, M. Galimberti and R. Comazzi	1601	Early cardiac toxicity of 4′-iodo-4′-deoxydoxorubicin
D. J. Th. Wagener, R. Somers, A. Santoro, J. Verweij, P. J. Woll, G. Blackledge, H. J. Schütte, M. A. Lentz and M. van Glabbeke for the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group	1604	Phase II study of nimustine in metastatic soft tissue sarcoma
P. Soubeyran, H. Eghbali, F. Bonichon, M. Trojani, P. Richaud and B. Hœrni	1606	Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients

J. S. Groeger, D. Bajorin, B. Reichman, I. Kopec, O. Atiq and M. K. Pierri	1613	Haemodynamic effects of recombinant interleukin-2 administered by constant infusion
V. J. Harvey, J. R. Hardy, S. Smith, W. Grove and B. C. Baguley	1617	Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer
M. J. Kajanti and S. O. Pyrhönen	1620	Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma
G.-T. Huang, T.-H. Wang, J.-C. Sheu, N. Daikuzono, J.-L. Sung, M.-Z. Wu and D.-S. Chen	1622	Low-power laserthermia for the treatment of small hepatocellular carcinoma
F. J. M. van Breukelen, K. Mattson, G. Giaccone, N. van Zandwijk, H. T. Planteydt, A. Kirkpatrick and O. Dalesio	1627	Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC lung cancer cooperative group
D. J. Dodwell, S. K. Abbas, A. R. Morton and A. Howell	1629	Parathyroid hormone-related protein$^{(50-69)}$ and response to pamidronate therapy for tumour-induced hypercalcaemia
J. Cassidy, C. Poole, E. Sharkie, W. P. Steward and S. B. Kaye	1633	The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon
M. E. L. van der Burg, A. S. Th. Planting, G. Stoter, C. McDaniel, C. J. Vecht and J. Verweij	1635	Phase I study of DABIS maleate given once every 3 weeks
G. Schwartsmann, E. Sprinz, M. Kronfeld, J. Vinholes, E. Sander, M. Zampese, R. Preger, L. Kalakun and A. L. Brunetto	1637	Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma
P. R. Twentyman and N. M. Bleehen	1639	Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A
A. D. Wennborg, E. Altiok, J. P. Moore, I. Ernberg and G. Klein	1643	Differential c-*myc* protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines
X.-F. Sun, S. Wingren, J. M. Carstensen, O. Stål, T. Hatschek, B. Boeryd, B. Nordenskjöld and H. Zhang	1646	*ras* p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma
C. C. Geilen, R. Haase, K. Buchner, T. Wieder, F. Hucho and W. Reutter	1650	The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C *in vitro* and antagonises phorbol ester-stimulated cell proliferation
T. Ebihara, N. Sakai and S. Koyama	1654	Suppression by sorted $CD8^+CD11b^-$ cells from T-cell growth factor-activated peripheral blood lymphocytes on cytolytic activity against tumour in patients with gastric carcinoma
S. Egyházi, J. Bergh, J. Hansson, P. Karran and U. Ringborg	1658	Carmustine-induced toxicity, DNA crosslinking and O^6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines
M. Lundqvist, J. Mark, K. Funa, N.-E. Heldin, G. Morstyn, B. Wedell, J. Layton and K. Öberg	1663	Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma
S. M. Scholl, B. Asselain, T. Palangie, T. Dorval, M. Jouve, E. G. Giralt, J. Vilcoq, J. C. Durand and P. Pouillart	1668	Neoadjuvant chemotherapy in operable breast cancer
E. Kovacs, T. Hajto and K. Hostanska	1672	Improvement of DNA repair in lymphocytes of breast cancer patients treated with *Viscum album* extract (Iscador)
J.-M. Tourani, V. Levy, J. Briere, R. Levy, C. Franks and J.-M. Andrieu	1676	Interleukin-2 therapy for refractory and relapsing lymphomas
L. Huschtscha, E. Rozengurt and W. F. Bodmer	1680	Growth factor requirements of human colorectal tumour cells: relations to cellular differentiation
L.-M. Ching, G. J. Finlay, W. R. Joseph and B. C. Baguley	1684	*In vitro* methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid
A. Boutan-Laroze, M. Mahjoubi, J. P. Droz, P. Charrot, P. Fargeot, P. Kerbrat, A. Caty, P. M. Voisin, M. Spielmann, A. Rey and B. Giraud	1690	M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder
H. Olsson and C. Ingvar	1694	Left handedness is uncommon in breast cancer patients
A. J. Sasco, B. Fontanière, M.-O. Charbaut-Lagarde, U. Kliebsch, P. Hamandjian, A.-E. Cornu-Lugrin, J.-P. Schnebelen, V. Sciortino and J. Fabry	1696	A systematic survey of breast cancer incidence in the Département of Rhône, France

Feature Articles

M. T. Goodman and G. N. Stemmermann 1701 Cancer registration and incidence in Hawaii

W. K. Cavenee, B. Ponder and E. Solomon 1706 Genetics and cancer

News 1709

Letters

W. Shiu, M. Tao and T. Leung 1710 Phase II study of combination vincristine, epirubicin and cyclophosphamide in advanced breast cancer in Chinese patients

H. S. R. Hosker, P. McArdle and P. A. Corris 1711 Alveolar macrophage function before and during treatment with cytotoxic chemotherapy in patients with small cell lung cancer

P. Marino, A. Preatoni, G. Buccheri, D. Ferrigno and A. Fruttero 1712 Increased levels of soluble interleukin-2 receptors in supernatants from peripheral blood mononuclear cells of patients with lung cancer

A. J. Sasco and B. Fontanière 1713 A population-based series of 10 male breast cancer cases

F. Russo, F. Buda, C. Buda, P. Aragona, G. Tessitori, G. Simon, S. Chillemi, N. Caristi and A. Faiella 1713 Acute megakaryoblastic leukaemia in a child

S. Culine, M. Mahjoubi, I. Philippot and J. P. Droz 1715 Treatment of good-risk disseminated non-seminomatous germ cell tumours: the less bleomycin, the more cisplatin?

E. Hippe, V. Jønsson, Hans von der Maase, J. C. Mathiesen and H. S. Poulsen 1715 Homoeostatic response criteria for cancer therapy

I. Monnet, P. Chariot, N. Azli, P. Ruffié, S. Voisin, J.-C. Saltiel, H. de Cremoux and E. Cvitkovic 1716 Severe mucositis after chemotherapy with vinorelbine, 5-fluorouracil, leucovorin and cisplatin

Corrections 1717

Supplement 1

H-J. Schmoll S1 Introduction: the clinical challenge

Methodology

R. J. Gralla, R. A. Clark, M. G. Kris and L. B. Tyson S5 Methodology in anti-emetic trials

Ondansetron–clinical reviews

D. R. Gandara S9 Progress in the control of acute and delayed emesis induced by cisplatin

M. Tonato S12 Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy

N. Marschner S15 Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review

M. A. Dicato S18 Oral treatment with ondansetron in an outpatient setting

R. F. Stevens S20 The role of ondansetron in paediatric patients: a review of three studies

Summary

H-J. Schmoll S22 Chairman's summary

Poster Abstracts

C. Evans, R. C. Stein, J. Davenport, L. Dougherty, L. Carruthers and R. C. Coombes S25 Comparison of anti-emetic efficacy of ondansetron with dexamethasone plus domperidone in refractory nausea and vomiting in patients receiving non-cisplatin chemotherapy regimens

A. du Bois, H. G. Meerpohl and A. Pfleiderer S25 Anti-emetic therapy with the 5-HT_3 antagonist ondansetron in cisplatin-induced vomiting refractory to standard anti-emetic regimens

C. Nürge, J. Casper, U. Genest, H. Wilke, C. H. Köhne-Wömpner, H-J. Schmoll and H. Poliwoda S25 Treatment of refractory nausea and vomiting with ondansetron in patients receiving non-cisplatin chemotherapy

B. Evans, V. Harvey, D. Mak, L. Neeve, G. Langley and D. Dickson S26 Ondansetron (GR38032F) controls carboplatin-induced vomiting resistant to standard anti-emetics

G. Fraschini, L. Esparza, A. Ciociola, D. Templeton, R. Walters and G. Hortobagyi S26 Anti-emetic activity of three oral dosages of ondansetron in patients receiving doxorubicin and cyclophosphamide

C. Oliva, E. Campora, M. G. Vidili and R. Rosso S26 Ondansetron (GR38032F) for the control of refractory chemotherapy-induced emesis

N. Marschner, M. Adler, G. A. Nagel and D. Christmann S26 Double-blind randomised trial of the anti-emetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide

M. Adler, N. Marschner, F. Jänicke and G. A. Nagel	S27	Anti-emetic efficacy of ondansetron in long-term therapy
D. Kennard, M. Butcher, J. Palmer, P. Beranek and G. W. Brown	S27	The anti-emetic efficacy, pharmacokinetics and safety of ondansetron in the elderly receiving cancer chemotherapy or radiotherapy

Supplement 4

M. Freund and S. E. Salmon	S1	Introduction
Review		
E. M. Bonnem	S2	Alpha interferon: the potential drug of adjuvant therapy: Past achievements and future challenges
Chronic Myelogenous Leukaemia		
N. Niederle, T. Moritz, O. Kloke, U. Wandl, D. May, R. Becher, T. Franz, B. Opalka and C. G. Schmidt	S7	Interferon alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: Initial response and long-term results in 54 patients
E. Morra, G. Alimena, M. Lazzarino, A. M. Liberati, E. Montefusco, P. Bernasconi, M. Mancini, E. Donti, S. Merante, F. Dianzani, F. Grignani, C. Bernasconi and F. Mandelli	S14	Evolving modalities of treatment with interferon alfa-2b for Ph^1-positive chronic myelogenous leukaemia
A. Broustet, J. Reiffers, G. Marit, D. Fiere, J. Jaubert, J. Reynaud, J. Pris, P. Bernard, C. Charrin, Z. Q. Wen, M. F. Berteas, N. Dastugue and Y. Parlier	S18	Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: Preliminary results of an Open French Multicentre Randomized Study
S. Asano, H. Ogura, K. Tani, T. Inoue, A. Tojo and K. Ozawa	S21	Several new approaches to improvement of alpha interferon therapy in chronic myelogenous leukaemia
M. Bessho, N. Kawai and K. Hirashima	S25	Interferon alfa-2b in the treatment of chronic myelogenous leukaemia
F. Guilhot, J-P Lamagnère, J. L. Harousseau, H. Tilly, P. Casassus, N. Ifrah, H. Rochant, F. Bauters, G. Dine, J. Tanzer	S26	A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph^1-positive chronic myelogenous leukaemia: Interferon alfa-2b and hydroxyurea with or without cytosine-arabinoside, preliminary results
R. Aitchison, E. McSweeney, L. Butler, L. Weidemann and A. C. Newland	S27	Cytogenetic and breakpoint cluster region (bcr) changes in chronic myelogenous leukaemia treated with low-dose alpha interferon
C. W. Park, C. H. Han, C. C. Kim and D. J. Kim	S27	Randomized, parallel-group comparison of interferon alfa-2b plus hydroxyurea versus hydroxyurea alone in patients with chronic myelogenous leukaemia in chronic phase
W. Arcese, F. R. Mauro, M. Screnci, G. Alimena, F. L. Coco, A. P. Iori, M. R. de Cuia, P. Fazi, E. Montefusco and F. Mandelli	S28	Interferon therapy for Ph^1-positive chronic myelogenous leukaemia patients relapsing after T-cell depleted allogeneic bone marrow transplantation
S. Shirakawa, T. Kobayashi, K. Nishii and K. Kita	S30	Treatment of Ph^1-positive chronic myelogenous leukaemia with recombinant interferon alfa-2b: A case report of complete cytogenetic response
Non-Hodgkin's Lymphoma		
T. Chisesi on behalf of the Non-Hodgkin's Lymphoma Cooperative Study Group	S31	Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study
C. G. A. Price, A. Z. S. Rohatiner, W. Steward, D. Deakin, N. Bailey, A. Norton, G. Blackledge, D. Crowther and T. A. Lister	S34	Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: Preliminary results of a randomized trial in progress
W. Hiddemann, M. Unterhalt, P. Koch, M. Nahler, R. Herrmann and J. van de Loo	S37	Alpha interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone
T. I. Mughal	S39	Role of interferon alfa-2b in the management of patients with advanced cutaneous T-cell lymphoma
Multiple Myeloma		
H. Ludwig, A. M. Cohen, H. Huber, D. Nachbaur, W. F. Jungi, H. Senn, P. Günczler, J. Schüller, S. Eckhardt, H. L. Seewann, F. Cavalli, E. Fritz and M. Micksche	S40	Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: Interim results

J. Westin, A. Cortelezzi, M. Hjorth, S. Rödjer, I. Turesson and G. Zador for a cooperative study group	S45	Interferon therapy during the plateau phase of multiple myeloma: An update of the Swedish study
J. F. San Miguel, M. Moro, J. Bladé, L. Guerras, J. Hernandez, R. Jimenez-Galindo, F. Ortega and M. Gonzalez	S48	Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy
A. Maniatis for the Greek Myeloma Study Group (GMSG)	S49	Maintenance treatment of multiple myeloma with alpha interferon versus an alternating schedule of alpha interferon and chemotherapy
M. Björkholm for the Myeloma Group of Central Sweden	S51	Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III
Haematologic Disorders		
L. C. Platanias and M. J. Ratain	S53	Hairy cell leukaemia: The role of alpha interferon
H. L. Seewann, R. Zikulnig, G. Gallhofer and C. Schmid	S58	Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b
S. J. Proctor	S63	Alpha interferon therapy in the treatment of idiopathic thrombocytopenic purpura
X. Yataganas, J. Meletis, E. Plata, N. Viniou, F. Deligiannis, C. Tsekoura, E. Voscaridou, V. Boussiotis, J. Rombos, G. Vayopoulos, C. Kittas and P. Fessas	S69	Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis
M. Giralt, D. Rubio, M. T. Cortés, J. San Miguel, J. L. Steegmann, J. Serena, J. M. Fernández-Rañada and A. López-Borrasca	S72	Alpha interferon in the management of essential thrombocythaemia
E. Montserrat, N. Villamor, A. Urbano-Ispizua, J-M. Ribera and C. Rozman	S74	Alpha interferon in chronic lymphocytic leukaemia
V. A. Boussiotis and G. A. Pangalis	S78	Interferon alfa-2b in stage A untreated B-chronic lymphocytic leukaemia patients
B. Koziner	S79	Alpha interferon in patients with progressive and/or recurrent Hodgkin's disease
C. Ferri, E. Marzo, G. Longombardo, F. Lombardini, F. Greco and S. Bombardieri	S81	Alpha interferon in the treatment of mixed cryoglobulinaemia patients
E. Lundgren, H. Hedman, G. Landberg, F. Chiang, G. Roos and R. Sanders	S82	Molecular events in B-cell activation and growth: Sensitivity to alpha interferon
Future Perspective on the Use of Interferons		
H. B. Muss	S84	The use of interferon in renal cell carcinoma
J. Atzpodien and H. Kirchner	S88	The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies
Panel Discussion	S92	All Speakers